Telomir Pharmaceuticals, Inc. announced on August 27, 2025, promising in vitro results for its lead drug candidate, Telomir-1, which appears to reset faulty DNA methylation patterns associated with cancer and aging. These findings suggest Telomir-1 could be a first-in-class epigenetic therapy with a dual mechanism of action.